{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:19:47Z","timestamp":1790443187460,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jpba.2022.114852","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T20:56:06Z","timestamp":1653339366000},"page":"114852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Highly-sensitive simultaneous quantitation of glucosylsphingosine and galactosylsphingosine in human cerebrospinal fluid by liquid chromatography\/tandem mass spectrometry"],"prefix":"10.1016","volume":"217","author":[{"given":"Shin-ichi","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.114852_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197159","article-title":"Value of glucosylsphingosine (lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review","volume":"21","author":"Revel-Vilk","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2022.114852_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0021-9258(18)97611-8","article-title":"The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue","volume":"240","author":"Brady","year":"1965","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2022.114852_bib3","first-page":"811","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"2014","author":"Ferraz","year":"1841","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpba.2022.114852_bib4","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jpba.2022.114852_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","article-title":"Krabbe disease: a galactosylsphingosine (psychosine) lipidosis","volume":"21","author":"Svennerholm","year":"1980","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.jpba.2022.114852_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/jnr.23838","article-title":"Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe\u2019s disease)","volume":"94","author":"Bradbury","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jpba.2022.114852_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cca.2013.01.017","article-title":"Determination of psychosine concentration in dried blood spots from newborns that were identified via newborn screening to be at risk for Krabbe disease","volume":"419","author":"Chuang","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2022.114852_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2017.05.015","article-title":"Psychosine, a marker of Krabbe phenotype and treatment effect","volume":"121","author":"Escolar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jpba.2022.114852_bib9","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1021\/acs.analchem.7b01442","article-title":"Glucosylceramide and glucosylsphingosine quantitation by liquid chromatography-tandem mass spectrometry to enable in vivo preclinical studies of neuronopathic Gaucher disease","volume":"89","author":"Hamler","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2022.114852_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2019.03.009","article-title":"Galactosylsphingosine does not interfere with the quantitation of plasma glucosylsphingosine levels in Gaucher patients","volume":"494","author":"Chuang","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2022.114852_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cca.2020.10.007","article-title":"Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS\/MS","volume":"511","author":"Beasley","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2022.114852_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jpba.2022.114852_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jpba.2022.114852_bib14","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2022.114852_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/mds.28144","article-title":"Common variants Coregulate expression of GBA and modifier genes to delay Parkinson\u2019s disease onset","volume":"35","author":"Schierding","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jpba.2022.114852_bib16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/geno.1999.5940","article-title":"The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression","volume":"62","author":"Li","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.jpba.2022.114852_bib17","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1073\/pnas.93.10.4638","article-title":"Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis","volume":"93","author":"Ichikawa","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S. A."},{"key":"10.1016\/j.jpba.2022.114852_bib18","doi-asserted-by":"crossref","first-page":"20097","DOI":"10.1073\/pnas.1912108116","article-title":"Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target","volume":"116","author":"Li","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2022.114852_bib19","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/hmg\/2.11.1841","article-title":"Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy","volume":"2","author":"Chen","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jpba.2022.114852_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020370","article-title":"Blood contamination in CSF and its impact on quantitative analysis of alpha-synuclein","volume":"9","author":"Barkovits","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jpba.2022.114852_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12987-019-0154-5","article-title":"Effect of blood contamination of cerebrospinal fluid on amino acids, biogenic amines, pterins and vitamins","volume":"16","author":"Batllori","year":"2019","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.jpba.2022.114852_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00690463","article-title":"Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies","volume":"65","author":"Conradi","year":"1984","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jpba.2022.114852_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcmd.2015.01.006","article-title":"Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard","volume":"54","author":"Mirzaian","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.jpba.2022.114852_bib24","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpba.2022.114852_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jpba.2022.114852_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease - links to Parkinson\u2019s disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.jpba.2022.114852_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mds.28846","article-title":"Plasma glucosylsphingosine in GBA1 mutation carriers with and without Parkinson\u2019s disease","volume":"37","author":"Surface","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jpba.2022.114852_bib28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mds.28936","article-title":"Reply to: no evidence that glucosylsphingosine is a biomarker for Parkinson disease","volume":"37","author":"Surface","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jpba.2022.114852_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28935","article-title":"No evidence that glucosylsphingosine is a biomarker for Parkinson\u2019s disease: statistical differences do not necessarily indicate biological significance","volume":"37","author":"Gleason","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jpba.2022.114852_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","article-title":"GBA mutations, glucosylceramide and Parkinson\u2019s disease","volume":"72","author":"Milenkovic","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.jpba.2022.114852_bib31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archneur.1970.00480300024003","article-title":"Studies in globoid (Krabbe) leukodystrophy (GLD). V. Controlled enzymic studies in ten human cases","volume":"23","author":"Austin","year":"1970","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jpba.2022.114852_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193438","article-title":"Analysis of age-related changes in psychosine metabolism in the human brain","volume":"13","author":"Marshall","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2022.114852_bib33","doi-asserted-by":"crossref","first-page":"eaax7462","DOI":"10.1126\/sciadv.aax7462","article-title":"Brain-targeted enzyme-loaded nanoparticles: a breach through the blood\u2013brain barrier for enzyme replacement therapy in Krabbe disease","volume":"5","author":"Del Grosso","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jpba.2022.114852_bib34","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2021.01.026","article-title":"Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease","volume":"29","author":"Heller","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jpba.2022.114852_bib35","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1021\/acs.jmedchem.9b02004","article-title":"Lead optimization of benzoxazolone carboxamides as orally bioavailable and CNS penetrant acid ceramidase inhibitors","volume":"63","author":"Di Martino","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522002734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522002734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:21:44Z","timestamp":1760001704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522002734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"alternative-id":["S0731708522002734"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114852","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly-sensitive simultaneous quantitation of glucosylsphingosine and galactosylsphingosine in human cerebrospinal fluid by liquid chromatography\/tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114852"}}